Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574540 | 0.95 | CA14 (0.53) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL19772708 | 0.93 | CA14 (0.51) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL14157489 | 0.90 | CA14 (0.58) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL6130651 | 0.90 | CA14 (0.52) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL15085740 | 0.89 | CA14 (0.53) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL896291 | 0.89 | CA14 (0.45) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL19929679 | 0.87 | CA14 (0.53) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL14175259 | 0.87 | CA12 (0.50) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL27252832 | 0.87 | CA14 (0.55) | CA14TDP1SSTR4HDAC6HDAC1 | |
| SCHEMBL25797677 | 0.87 | CA14 (0.59) | CA14TDP1SSTR4HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11623922-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-04-11 | — | — | US | disclosed |
| US-20200331886-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331886-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| EP-3692020-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068772-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068772-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| US-8084643-B2 | Nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs,including salts; veterinary medicine; nonhydrolyzing as needed to maintain the prodrug in aqueous solution in the subjects system until appropriate; cattle drinking water; bovine respiratory disease | INTERVET INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188556-A1 | Water-Soluble Prodrugs of Florfenicol and its Analogs | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
| EP-0815081-B1 | PIPERIDINYL-2-ALKYL SUBSTITUTED LINEAR POLYAMINES FOR THE REDUCTION OF INTRACELLULAR, ENDOGENIC POLYAMINE LEVELS SUCH AS PUTRESCINE, SPERMIDINE AND SPERMINE, AND THEIR IMPACT ON CELL PROLIFERATION | NOVARTIS AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-5834486-A | ANTIPROLIFERATIVE, ANTIPROTOZOA AGENTS | NOVARTIS AG (CH) | 1998-11-10 | — | — | US | disclosed |
| EP-0815081-A1 | PIPERIDINYL-2-ALKYL SUBST. LINEAR POLYAMINES FOR THE REDUCTION OF INTRACELLULAR, ENDOGENIC POLYAMINE LEVELS SUCH AS PUTRESCINE, SPERMIDINE AND SPERMINE, AND THEIR IMPACT ON CELL PROLIFERATION | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028425-A1 | PIPERIDINYL-2-ALKYL SUBST. LINEAR POLYAMINES FOR THE REDUCTION OF INTRACELLULAR, ENDOGENIC POLYAMINE LEVELS SUCH AS PUTRESCINE, SPERMIDINE AND SPERMINE, AND THEIR IMPACT ON CELL PROLIFERATION | NOVARTIS AG (CH) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623922-B2 | Compounds | NLRP3, NOD1, NLRP1 | CA14 4070/4885TDP1 1642/4885SSTR4 2960/4885 |
| US-20200331886-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | CA14 4548/4885TDP1 1391/4885SSTR4 3437/4885 |
| US-20080188556-A1 | Water-Soluble Prodrugs of Florfenicol and its Analogs | PFAS, ADH5, SI | CA14 1565/4885TDP1 860/4885SSTR4 3399/4885 |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | CA14 4764/4885TDP1 4687/4885SSTR4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.